CLCN3: A Potential Drug Target and Biomarker (G1182)

Target Name: CLCN3

NCBI ID: G1182

CLCN3

CLCN3: A Potential Drug Target and Biomarker

CLCN3 (C-lineage, N-methyl-L-citrate aminotransferase 3) is a protein that is expressed in various tissues, including the brain, heart, liver, and kidneys. It is a member of the superfamily of proteins known as the N-methyl-L-citrate aminotransferase (NMCT) family, which is characterized by the presence of a specific catalytic active site that is involved in the transfer of aminotransferase activity from the substrate to the Michaelis-Menten constant (KM) of the enzyme.

The primary function of CLCN3 is to catalyze the conversion of N-methyl-L-citrate (NMC) to N-methyl-L-glutamate (NMG), which is a crucial step in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. This conversion is critical for the production of energy in the form of ATP from the energy-rich NMC, which is then used by the cell to maintain various physiological processes.

LCCN3 is expressed in various tissues and is involved in the development, maintenance, and regulation of various physiological processes in the body. For example, it has been shown to be involved in the regulation of cell growth, differentiation, and survival. It has also been linked to the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Due to its involvement in various physiological processes and its potential role in the development of various diseases, CLCN3 has been identified as a potential drug target. Researchers have been exploring the use of drugs that can modulate CLCN3 activity to treat various diseases. One approach is to target CLCN3 directly with small molecules, such as inhibitors or modulators, in order to reduce its activity and prevent it from participating in the physiological processes that it is involved in.

Another approach is to identify CLCN3-associated biomarkers that can be used as targets for diagnostic tests or therapeutic interventions. For example, researchers have used CLCN3 as a biomarker to diagnose neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. They have found that the level of CLCN3 is significantly increased in the brains of patients with these diseases, and that inhibitors of CLCN3 activity have been shown to be effective in treating these conditions.

In addition to its potential use as a drug target and biomarker, CLCN3 is also of interest as a potential therapeutic intervention. Studies have shown that modulating CLCN3 activity can have a beneficial effect on various physiological processes, including metabolism, inflammation, and stress resistance. For example, researchers have found that inhibitors of CLCN3 activity have the potential to treat various metabolic disorders, such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).

In conclusion, CLCN3 is a protein that is expressed in various tissues and is involved in the conversion of N-methyl-L-citrate to N-methyl-L-glutamate, which is a crucial step in the production of energy in the form of ATP. It is also involved in the regulation of various physiological processes and has been linked to the development and progression of various diseases. As a result, CLCN3 has the potential to be a drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand the role of CLCN3 in these processes and to develop effective therapies that can modulate its activity.

Protein Name: Chloride Voltage-gated Channel 3

Functions: Strongly outwardly rectifying, electrogenic H(+)/Cl(-)exchanger which mediates the exchange of chloride ions against protons (By similarity). The CLC channel family contains both chloride channels and proton-coupled anion transporters that exchange chloride or another anion for protons (PubMed:29845874). The presence of conserved gating glutamate residues is typical for family members that function as antiporters (PubMed:29845874)

The "CLCN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLCN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets